Intercell AG

euro adhoc: Intercell AG
other
European Patent granted for IntercellÂ’s synthetic adjuvant IC31TM

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

26.04.2006

Intercell (VSE, "ICLL") announced today that the European Patent Office has granted an additional key patent covering a component of IntercellÂ’s novel proprietary synthetic adjuvant IC31TM. The newly issued patent (EP 1 326 634 B) specifically covers the peptide (KLK) component of IC31TM. A separate patent (EP 1 296 713 B), which was issued in 2003, covers the second component of the adjuvant, an oligonucleotide (I-ODN). Both patents together provide broad patent protection for the use of IC31TM as a B- and T-cell adjuvant in vaccines.

"With the issuance of this patent, we have succeeded in establishing solid patent coverage for our innovative adjuvant, IC31TM", states Alexander von Gabain, Chief Scientific Officer of Intercell. "The market demand for novel adjuvants which are safe and potent is growing. We are convinced that IC31TM will play a key role in our future vaccine development programs and those of our strategic partners, which include major players in the vaccine industry."

About IC31TM

IC31TM is an adjuvant that induces T-cell and B-cell responses by using a unique synthetic formulation which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required.

Intercell currently uses IC31™ in collaborations with a number of global vaccine companies and biotech companies. These collaborations include the development of a tuberculosis vaccine in Phase I clinical trials, which has been partnered with the Danish Statens Serum Institut, and the development of a therapeutic Hepatitis B vaccine with SciGen Ltd.

@@start.t2@@end of announcement                                                 euro adhoc 26.04.2006 07:30:00
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: